Cardiff Oncology Inc is a biotechnology company focused on developing innovative cancer therapies aimed at treating solid tumors
The company is dedicated to uncovering new treatment options for patients through its proprietary drug candidates and advanced research platforms. By leveraging scientific expertise and clinical research, Cardiff Oncology aims to address significant unmet needs in oncology, with an emphasis on enhancing patient outcomes and quality of life. Through collaboration with healthcare professionals and ongoing clinical trials, the company strives to bring novel therapeutics to market and contribute to the evolving landscape of cancer treatment.
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios. Predominantly utilized before and after surgery, these drugs are pivotal in managing the disease. Significant research efforts are focused on targeted therapies tailored to specific breast cancer types, particularly those characterized by overexpression of human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers, constituting 15% to 20% of cases, exhibit heightened aggressiveness, necessitating targeted interventions. Targeted drug therapy, including immunotherapy, directly addresses proteins on cancer cells, impeding their growth and proliferation. With HER2-targeted drugs demonstrating efficacy in inhibiting tumor progression, the market witnesses a surge in the development and adoption of such therapies to meet the demand for more effective treatments in combating breast cancer. According to a report from BioSpace, the global breast cancer drugs market size, which was valued at USD 32.93 billion in 2023 is projected to surpass around USD 78.61 billion by 2033, registering a CAGR of 9.09% over the forecast period of 2024 to 2033. North America dominated the market with the largest revenue share of 38.61% in 2023. Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, AbbVie (NYSE: ABBVNYSE), Cardiff Oncology, Inc. (NASDAQ: CRDFCRDF).
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dropping, 0.01% to 5,137.05.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.23% to 39,084.47 while the NASDAQ rose 1.22% to 16,287.91. The S&P 500 also rose, gaining, 0.78% to 5,135.86.
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.02% to 39,005.87 while the NASDAQ rose 0.63% to 16,193.95. The S&P 500 also rose, gaining, 0.40% to 5,116.75.
Cardiff Oncology's clinical update on ONSEMBLE trial data for onvansertib in second-line RAS-mutated metastatic colorectal cancer. Discover efficacy findings and the company's strategic shift towards first-line RAS-mutated mCRC.
Shares of NetApp, Inc. (NASDAQNTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.
